Pfizer’s revenue declines as it faces more biosimilar competition

Pfizer second-quarter earnings jumped thanks to rising sales of key drugs, but its overall revenue declined as the drugmaker was dogged by increased biosimilar competition and the divestiture of Hospira Infusion Systems.

Read the full post at Modern Healthcare Breaking News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive